M. Vanvolkenburg

发表

Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion.

K. Brayman, J. Parker, R. Ketchum, 1995, Biochemical and biophysical research communications.

Synergistic effect on insulin secretion from INS-1 cells of a sulfonylurea and a phosphodiesterase 3 inhibitor.

F. Gao, J. Parker, M. Vanvolkenburg, 2004, Life sciences.

Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase.

Carolyn B Levy, R. McPherson, J. Treadway, 1998, Diabetes.

CJ-21,164, a new D-glucose-6-phosphate phosphohydrolase inhibitor produced by a fungus Chloridium sp.

N. Yoshikawa, H. Nishida, Y. Kojima, 2002, The Journal of antibiotics.

Thielavins as glucose-6-phosphatase (G6Pase) inhibitors: producing strain, fermentation, isolation, structural elucidation and biological activities.

N. Kojima, N. Yoshikawa, H. Nishida, 2002, The Journal of antibiotics.

Development of a fluorescence-based in vivo phagocytosis assay to measure mononuclear phagocyte system function in the rat

K. Tartaro, J. Kreeger, D. Wilkie, 2015, Journal of immunotoxicology.

Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III.

D. Hargrove, N. A. Nardone, J. Parker, 1997, Biochemical and biophysical research communications.

Binding site on the murine IFN-gamma receptor for IFN-gamma has been identified using the synthetic peptide approach.

S. Russell, H. Johnson, M. Vanvolkenburg, 1993, Journal of immunology.

(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

Zhengrong Zhao, Dennis E Danley, M. Ammirati, 2007, Bioorganic & medicinal chemistry letters.

cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.

M. Ammirati, D. Danley, S. Wright, 2006, Journal of medicinal chemistry.

(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.

M. Ammirati, D. Danley, R. McPherson, 2009, Bioorganic & Medicinal Chemistry Letters.

Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.

P. Loria, D. Hepworth, S. Bhattacharya, 2014, ACS medicinal chemistry letters.

(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.

M. Ammirati, D. Danley, R. McPherson, 2009, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors.

M. Ammirati, R. McPherson, X. Qiu, 2007, Bioorganic & medicinal chemistry letters.